Q32 Bio Inc. (QTTB)
ValueMarkers Composite Index
99% above intrinsic value ($3)
Q32 Bio Inc. (QTTB) — VMCI valuation read
The headline on Q32 Bio Inc. (QTTB) is a 63/100 VMCI score, set against a Healthcare sector median of 50. That 13-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.
QTTB insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.
**Investor frame.** QTTB trades at 25.0x earnings, 39% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 3.5x is the binding constraint on the bear case sets the risk side, the three lines a value buyer reads first on QTTB.
QTTB rose 3.2% over the trailing 7 days, with a -5.8% read on a 30-day basis.
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.
- SPRINT.ST - Sprint Bioscience AB (publ)
- CO - Global Cord Blood Corporation
- 096760.KS - JW Holdings Corporation
- 1526.HK - Rici Healthcare Holdings Limited
- 0T6G.L - Q32 Bio Inc.
- LTGHY - Life Healthcare Group Holdings Limited
- LTGHY - Life Healthcare Group Holdings Limited
- 9594.SR - Al-Modawat Specialized Medical Co.